Portage Biotech Announces New Appointments to its Management Team and Board of Directors
Leading biopharma executive
Experienced financial consultant
The new appointments come at the cusp of an exciting new year for Portage. The company expects to report initial safety data of its invariant natural killer T cell (iNKT) agonist programs, PORT-2 and PORT-3, later in Q1 2022.
“I am thrilled to announce these new additions to our executive team and Board of Directors to support Portage’s operations and activities as we head into what will be a critical year, especially for our iNKT programs,” said Dr.
“I am exctied to join Portage at this pivotal time of growth and progress,” said
As Chief Accounting Officer,
Further info on new members of Portage’s Board of Directors:
Jim Mellonis an author, entrepreneur and investor. He was one of the founders of Portage Biotechand is the co-author of five books, all written with a view toward identifying emerging thematic trends leading to investment opportunities. He is a founder and Executive Director of Agronomics Limited (LSE:ANIC) an investment vehicle for cellular agriculture and cultivated meat. He has a particular interest in longevity research and is currently the co-founder and chairman of anti-aging biopharma company Juvenescence. He is also a non-executive director of Condor Gold plc, the Executive Chairman of the Board of Manx Financial Group plc, Co-founder and Non-Executive Director of Bradda Head Lithium (LSE:BHL.L), and the non-executive Chairman of the Board of SalvaRx Group plc. He is also Co-founder and Chairman of Endurance RP. Mr. Mellonstudied Philosophy, Politics & Economics at Oxford University. Linda M. Kozickhas more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology with a focus in immuno-oncology. Prior to retiring she held leadership positions at Bristol Myers Squibb and was instrumental to Opdivo and Yervoy product management and portfolio strategy. In addition to Portage, she currently serves on the Board of Directors for RAPT Therapeutics, Inc. and Artiva Biotherapeutics. Ms. Kozickreceived her B.S. in Medical Technology and M.S. in Molecular Immunology from SUNY Upstate Medical Center, and her MBA from Chapman University. Mark Simonhas over 30 years advising experience for biotech and pharma companies as an investment banker and research analyst. He is the Co-founder and an advisor of Torreya Capital, LLC, a global investment bank serving companies in the life sciences industry. Before co-founding Torreya Capital, LLC, he was a Managing Director and the head of life sciences investment banking at Citigroup, where he covered global biopharmaceutical companies, and also served as a Managing Director and Senior Biotechnology Research Analyst at Robertson Stephens. Mr. Simonserves on the boards of Cabaletta Bio and several disease advocacy and philanthropic foundations. Mr. Simonholds a B.A. in History from Columbia Collegeand an MBA from Harvard Business School.
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech, or find us on LinkedIn at
This news release contains statements about the Company’s information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Source: Portage Biotech, Inc.